NCT03395080 2025-08-01
P204
Leap Therapeutics, Inc.
Phase 2 Completed
Clinical Trials
12 trialsNCT04383210 2025-04-03
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Phase 2 Terminated
NCT03073525 2023-04-05
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Gradalis, Inc.
Phase 2 Completed
NCT01420081 2019-01-08
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
Pfizer
Phase 2 Terminated
NCT01379534 2015-05-20
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Novartis
Phase 2 Completed
NCT00050440 2013-01-08
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT01290406 2012-06-21
BEZ235 Trial in Patients With Advanced Endometrial Carcinoma
Novartis
Phase 2 Withdrawn
NCT00776074 2010-06-22
A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.
Takeda
Phase 2 Completed
NCT00377520 2009-11-20
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00782041 2009-09-15
Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
Sanofi
Phase 2 Terminated
NCT00121030 2007-12-24
Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy
Amgen
Phase 2 Completed
NCT00190918 2007-08-09
A Trial for Patients With Gestational Trophoblastic Disease
Eli Lilly and Company
Phase 2 Completed